Latest Conference Articles

Four Key Areas Are Focus of ASCO/SABCS Highlights

Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.

29th Annual Miami Breast Cancer Conference Opens

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

Miami Breast Cancer Conference Founder Keeps Focus on Future

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Dr. Steensma Discusses Iron Chelation Therapy for MDS

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

Managing Chronic Myeloid Leukemia Treatment

Certain characteristics of patients with CML can affect therapeutic outcomes.

New Model Helps Guide Treatment Options in CLL

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

Dr. Erba Describes Proper Diagnostic Testing of CML

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

2012 ONS Congress Coverage Coming Soon

Meeting coverage from the 2012 Oncology Nursing Society Congress held at the New Orleans Ernest N. Morial Convention Center, from May 3-6, 2012.

Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCL

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

Current Trends in the Treatment of Newly Diagnosed Myeloma

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Ansell on Waldenstrom Macroglobulinemia Types

Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia

Noted Researcher Sees ERT as Remarkable Beginning

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Same Mission, New Role for Genzyme Executive: Head of Rare Diseases Committed to Patients

Rogerio Vivaldi, MD, has vivid memories of the first patient with Gaucher disease ever treated in Brazil with enzyme replacement therapy.

Lysosomal Storage Disorders: Marking Milestones and Moving Forward

The mood of the ICHG/ASHG 2011 congress often seemed buoyant as researchers discussed the doors that technology is helping to open.

Dr. Grabowski Explains the Effects of Enzyme Therapy

Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy

Dr. Mistry Discusses His Experience With Gaucher Disease

Pramod K. Mistry, MD, PhD, from Yale University, discusses Gaucher disease

Dr. Mato on the Benefits of the JTCC Retrospective Trial

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Photos From the 2011 ASH Annual Meeting and Exposition

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

Ponatinib Continues March to Potential Front-line Use in CML

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. Kochenderfer Discusses the B-cell Antigen CD19

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19